Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9369306 | 0.68 | KDM4E (0.34) | KDM4EMAPK1ATMHSP90AA1 | |
| SCHEMBL31023619 | 0.64 | KDM4E (0.38) | KDM4ELMNATDP1MAPK1ATM | |
| SCHEMBL122449 | 0.64 | — | — | |
| SCHEMBL102781 | 0.61 | MEN1 (0.37) | KDM4ELMNATDP1MAPK1ATM | |
| SCHEMBL30969099 | 0.61 | KDM4E (0.44) | KDM4ELMNATDP1MAPK1ATM | |
| SCHEMBL20756367 | 0.61 | KDM4E (0.44) | KDM4ELMNATDP1MAPK1ATM | |
| SCHEMBL3058111 | 0.61 | KDM4E (0.44) | KDM4ELMNATDP1MAPK1ATM | |
| SCHEMBL5841466 | 0.61 | DRD2 (0.37) | KDM4ELMNATDP1MAPK1ATM | |
| SCHEMBL6315604 | 0.60 | PKM (0.41) | KDM4ELMNATDP1MAPK1ATM | |
| SCHEMBL6315597 | 0.60 | PKM (0.41) | KDM4ELMNATDP1MAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113321658-B | Dibenzooxepidine fluorescent functional molecule and preparation and application thereof | 华南农业大学 | 2022-03-25 | — | — | CN | claimed |
| CN-113321658-A | Dibenzooxepidine fluorescent functional molecule and preparation and application thereof | 华南农业大学 | 2021-08-31 | — | — | CN | claimed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | claimed |
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | claimed |
| US-6498190-B1 | TREATMENT OF NASAL OCCLUSION AND MAST CELL DYSFUNCTION DISEASES; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2002-12-24 | — | — | US | claimed |
| US-5872115-A | COMPOUNDS FOR TREATMENT OF HYPERCHOLESTEROLEMIA, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISEASE OR ATHEROSCLEROSIS | GRELAN PHARMACEUTICAL CO. LTD. (JP) | 1999-02-16 | — | — | US | claimed |
| EP-0837052-A1 | BICYCLIC AMINO DERIVATIVES AND PGD 2 ANTAGONIST CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 1998-04-22 | — | — | EP | claimed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | claimed |
| US-4560447-A | Electrolytic process for preparation of α-alkylated acetic acid derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | claimed |
| US-20240231224-A9 | HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF | LAM RESEARCH CORPORATION | 2024-07-11 | — | — | US | disclosed |
| WO-2024137876-A2 | SURFACE MODIFICATION OF METAL CATALYSTS WITH HYDROPHOBIC LIGANDS OR IONOMERS | TWELVE BENEFIT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240200208-A1 | CO2 PURIFICATION AND REDUCTION SYSTEMS | SUMITOMO MITSUI BANKING CORPORATION | 2024-06-20 | — | — | US | disclosed |
| US-20240192590-A1 | APPARATUS AND PROCESS FOR EUV DRY RESIST SENSITIZATION BY GAS PHASE INFUSION OF A SENSITIZER | LAM RESEARCH CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2024123514-A1 | CO2 PURIFICATION AND REDUCTION SYSTEMS | TWELVE BENEFIT CORPORATION (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0742208-A1 | 2-Ureido-benzamide derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| EP-0107134-B1 | TRICYCLIC ANTIDEPRESSANT DRUG IMMUNOGENS, ANTIBODIES, LABELED CONJUGATES, AND RELATED DERIVATIVES | MILES LABORATORIES, INC. (US) | 1986-04-09 | — | — | EP | disclosed |
| US-4560447-A | Electrolytic process for preparation of α-alkylated acetic acid derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | disclosed |
| US-4495281-A | CONTAINS DIBENZO(A,D)CYCLOHEPTENE; DIBENZ!B,F) AZEPINE AND DIBENZ(B,E)OXEPIN RINGS | MILES LABORATORIES, INC. (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0107134-A1 | Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives | MILES LABORATORIES, INC. (US) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | KDM4E 636/4885LMNA 2273/4885TDP1 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.